ArticleVaccine2022

Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer.

Paulo Gabriel Siqueira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.